Systemic sclerosis & Raynaud's
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial
Authors' conclusion
Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity.
Study context
- Population
- Patients with dcSSc from 2 Dutch centres who participated in the ASTIS trial
- Participants
- 21 patients2 Dutch centres
- Comparison
- Autologous HSCT vs CYC in dcSSc; serum tenascin C (TENC), cartilage oligomeric matrix protein (COMP) and COL4A1 vs modified Rodnan skin score (mRSS)
- HSCTn = 10
- CYCn = 11reference
- Primary endpoint
- Relationship of serum TENC, COMP and COL4A1 with mRSS as cross-sectional and dynamic biomarkers of skin involvement
- Follow-up
- Baseline, 12 and 24 months
Methodological detailsbiomarker study, linear mixed-effects models, multivariable linear regression
- Biomarker study
- Linear mixed-effects models
- Multivariable linear regression
Primary result
As reported in the abstract
Cross-sectional correlation of analytes with mRSS
COL4A1 correlation with mRSS at multivariable analysis
β = 0.01
p = 0.001
Further findings
ng/mL
| Outcome | HSCT | CYC | P value |
|---|---|---|---|
| Change in COL4A1 concentration · 24 monthsGreater reduction with HSCT | −81 | −27.4 | P = 0.029 |
Dynamic biomarkers: change in COMP vs mRSS change
- Only changes in COMP associated with mRSS change
- r = 0.013; p = 0.012
Original publication
A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial. Arthritis Res Ther. Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →